Purchase Order 75F40124P00219
Award Date 6/17/24
Potential Completion Date 7/23/26
Potential Value $234K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Singapore
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Food and Drug Administration awarded a firm fixed price purchase order valued at $534,536 to Illumina, Inc., a San Diego-based biotechnology company specializing in genomic sequencing technologies, for one Illumina NextSeq 2000 Sequencer with post-warranty correction and remedial repair services. The contract, awarded on August 17, 2023, with an ultimate completion date of December 11, 2028, was issued under a combined synopsis/solicitation posted in May 2023. The sequencer will be delivered...
- The Department of Health and Human Services Food and Drug Administration awarded a $534,031 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System to be delivered to Silver Spring, Maryland. The solicitation notice indicated the FDA requires this sequencing system to adapt standard operating procedures for its currently installed Illumina NextSeq 500 model, scale up sequencing...
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
- The Food and Drug Administration (FDA) awarded a purchase order to Illumina, Inc. for an Illumina MiSeq i100Plus Sequencing System with a ceiling value of $97,054. The contract, which carries no set-aside designation, was awarded on September 18, 2025, with an ultimate completion date of October 20, 2025. The MiSeq i100Plus is an advanced DNA and RNA sequencing instrument that enables genomic analysis and research applications. Performance will take place at Illumina's San Diego, California...
- This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a biotechnology company specializing in genetic sequencing and genomic analysis technologies. The contract is for the procurement of an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System, including installation, training, warranty, and preventative maintenance. The original solicitation was a Request for Quotation (RFQ) with a potential incumbent of Illumina, Inc....
- The U.S. Food and Drug Administration awarded a $219,300 firm fixed price purchase order to Illumina, Inc. for a NextSeq 2000 Sequencing System. This award was not subject to any set-aside provisions. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has been awarded past federal contracts with agencies such as the NIH, CDC, USDA, and VA to provide a range of sequencing systems and related products. The award references an original small business...
- The Department of Health and Human Services Food and Drug Administration awarded a $457,531.00 firm fixed price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract is for the delivery of an ILLUMINA NEXTSEQ 2000 SEQUENCING SYSTEM, plus a preventative maintenance agreement, to be performed in Silver Spring, Maryland. This award does not have a set-aside designation. Illumina has a history of providing sequencing systems and related...
- The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $341,700 purchase order to Illumina, Inc. to provide one (1) Illumina NextSeq 2000 System. The place of performance for this firm fixed price contract is Silver Spring, Maryland. The period of performance is from September 29, 2022 through October 29, 2023. The NextSeq 2000 System is a benchtop high-throughput sequencing platform that enables DNA and RNA sequencing applications. No applicable...
- The Department of Health and Human Services Food and Drug Administration awarded a $169,505.48 firm fixed price purchase order to Illumina, Inc. of Laurel, Maryland for an Illumina NextSeq 50 System Check. The contract has a period of performance through February 10, 2025 to deliver product care services for the NextSeq 50 sequencing system. No set-aside provisions were applied to this award made by the FDA to support its regulatory and public health responsibilities through genomic analysis...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for NEXTSEQ 500 comprehensive plan service maintenance for two NextSeq 500 sequencing systems at the FDA's location in Berwyn Heights, Maryland. The contract has a ceiling value of $265,801.32 and a period of performance through September 30, 2021. This contract does not have a...